Stock Analysis on Net
Stock Analysis on Net

Eli Lilly & Co. (NYSE:LLY)

Price to FCFE (P/FCFE)

Microsoft Excel

Free Cash Flow to Equity (FCFE)

Eli Lilly & Co., FCFE calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net income 10,590,000 5,240,400 6,244,800 5,581,700 6,193,700
Net noncash charges 3,612,900 2,054,700 854,100 2,701,600 1,053,300
Other changes in operating assets and liabilities, net of acquisitions and divestitures (5,385,000) (3,055,000) (14,500) (1,022,600) (747,400)
Net cash provided by operating activities 8,817,900 4,240,100 7,084,400 7,260,700 6,499,600
Purchases of property and equipment (5,057,800) (3,447,600) (1,854,300) (1,309,800) (1,387,900)
Net change in short-term borrowings (1,851,800) 4,691,400 1,498,000 (4,000) (1,494,200)
Proceeds from issuance of long-term debt 11,417,100 3,958,500 — 2,410,800 2,062,300
Repayments of long-term debt (664,200) — (1,560,000) (1,905,400) (276,500)
Free cash flow to equity (FCFE) 12,661,200 9,442,400 5,168,100 6,452,300 5,403,300

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Item Description The company
FCFE Free cash flow to equity is the cash flow available to Eli Lilly & Co. equity holders after all operating expenses, interest, and principal payments have been paid and necessary investments in working and fixed capital have been made. Eli Lilly & Co. FCFE increased from 2022 to 2023 and from 2023 to 2024.

Price to FCFE Ratio, Current

Eli Lilly & Co., current P/FCFE calculation, comparison to benchmarks

Microsoft Excel
No. shares of common stock outstanding 948,169,999
Selected Financial Data (US$)
Free cash flow to equity (FCFE) (in thousands) 12,661,200
FCFE per share 13.35
Current share price (P) 873.12
Valuation Ratio
P/FCFE 65.39
Benchmarks
P/FCFE, Competitors1
AbbVie Inc. 14.14
Amgen Inc. 26.09
Bristol-Myers Squibb Co. 8.63
Danaher Corp. 43.00
Gilead Sciences Inc. 19.18
Johnson & Johnson 12.86
Merck & Co. Inc. 16.64
Pfizer Inc. 3.60
Regeneron Pharmaceuticals Inc. 20.65
Thermo Fisher Scientific Inc. 29.99
Vertex Pharmaceuticals Inc. 37.58
P/FCFE, Sector
Pharmaceuticals, Biotechnology & Life Sciences 17.30
P/FCFE, Industry
Health Care 17.37

Based on: 10-K (reporting date: 2024-12-31).

1 Click competitor name to see calculations.

If the company P/FCFE is lower then the P/FCFE of benchmark then company is relatively undervalued.
Otherwise, if the company P/FCFE is higher then the P/FCFE of benchmark then company is relatively overvalued.

Price to FCFE Ratio, Historical

Eli Lilly & Co., historical P/FCFE calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
No. shares of common stock outstanding1 948,169,999 950,164,452 950,296,118 952,347,126 958,425,693
Selected Financial Data (US$)
Free cash flow to equity (FCFE) (in thousands)2 12,661,200 9,442,400 5,168,100 6,452,300 5,403,300
FCFE per share3 13.35 9.94 5.44 6.78 5.64
Share price1, 4 867.05 745.91 329.07 238.31 206.46
Valuation Ratio
P/FCFE5 64.93 75.06 60.51 35.17 36.62
Benchmarks
P/FCFE, Competitors6
AbbVie Inc. 13.57 17.37 22.66 18.76 13.16
Amgen Inc. 25.50 4.71 8.32 13.52 11.06
Bristol-Myers Squibb Co. — 7.52 22.85 16.17 7.80
Danaher Corp. — 53.08 32.04 20.75 44.62
Gilead Sciences Inc. — 12.81 15.22 12.70 5.98
Johnson & Johnson 12.67 24.31 16.73 23.28 15.60
Merck & Co. Inc. — 24.48 22.40 18.72 17.85
Pfizer Inc. — 3.82 10.56 8.88 —
Regeneron Pharmaceuticals Inc. 21.27 26.52 19.29 10.35 13.30
Thermo Fisher Scientific Inc. — 31.16 27.98 13.44 18.58
Vertex Pharmaceuticals Inc. — 33.45 19.91 26.08 18.46
P/FCFE, Sector
Pharmaceuticals, Biotechnology & Life Sciences — 16.91 19.28 16.49 17.09
P/FCFE, Industry
Health Care — 16.85 18.12 17.81 17.23

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Data adjusted for splits and stock dividends.

2 See details »

3 2024 Calculation
FCFE per share = FCFE ÷ No. shares of common stock outstanding
= 12,661,200,000 ÷ 948,169,999 = 13.35

4 Closing price as at the filing date of Eli Lilly & Co. Annual Report.

5 2024 Calculation
P/FCFE = Share price ÷ FCFE per share
= 867.05 ÷ 13.35 = 64.93

6 Click competitor name to see calculations.

Valuation ratio Description The company
P/FCFE Price to free cash flow to equity is cash valuation indicator of stockholders’ equity. Eli Lilly & Co. P/FCFE ratio increased from 2022 to 2023 but then slightly decreased from 2023 to 2024 not reaching 2022 level.